Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neoleukin Therapeutics Inc
(NQ:
NLTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 18, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Neoleukin Therapeutics Inc
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
December 14, 2023
From
Neoleukin Therapeutics, Inc.
Via
GlobeNewswire
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
September 22, 2023
From
Neoleukin Therapeutics, Inc.
Via
GlobeNewswire
NEOLEUKIN THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX
July 25, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sculptor Capital Management Inc. (NYSE – SCU), Neoleukin Therapeutics, Inc. (Nasdaq - NLTX), Pardes Bioscience, Inc. (Nasdaq – PRDS), Great Ajax Corp. (NYSE – AJX)
July 24, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Neoleukin Therapeutics, Inc. (Nasdaq - NLTX), Pardes Bioscience, Inc. (Nasdaq – PRDS), Kaleyra, Inc. (NYSE – KLR), Great Ajax Corp. (NYSE – AJX)
July 18, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
NLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to Shareholders
July 18, 2023
From
Halper Sadeh LLC
Via
Business Wire
Neurogene and Neoleukin Announce Definitive Merger Agreement
July 18, 2023
From
Neoleukin Therapeutics, Inc.
Via
GlobeNewswire
Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition
March 08, 2023
From
Neoleukin Therapeutics, Inc.
Via
GlobeNewswire
Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting
December 12, 2022
Targeted, precision-tuned agonist of IL-2 receptor selectively expands regulatory T cells
From
Neoleukin Therapeutics, Inc.
Via
GlobeNewswire
Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update
November 14, 2022
From
Neoleukin Therapeutics, Inc.
Via
GlobeNewswire
Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting
November 03, 2022
From
Neoleukin Therapeutics, Inc.
Via
GlobeNewswire
Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
July 27, 2022
From
Neoleukin Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.